Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100PNBN
Period2017-01-01 → 2017-12-31
Filed2022-11-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amends S100CP6F.

Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥229m2017-01-01 → 2017-12-31StandaloneNet sales
Revenue¥178m2016-01-01 → 2016-12-31StandaloneNet sales
Revenue¥121m2015-01-01 → 2015-12-31dStandaloneNet sales (5-year summary)
Revenue¥29m2014-01-01 → 2014-12-31dStandaloneNet sales (5-year summary)
Revenue¥1m2013-01-01 → 2013-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.1bn2017-01-01 → 2017-12-31StandaloneOperating income
Operating income−¥861m2016-01-01 → 2016-12-31StandaloneOperating income
Ordinary income−¥1.1bn2017-01-01 → 2017-12-31StandaloneOrdinary income
Ordinary income−¥864m2016-01-01 → 2016-12-31StandaloneOrdinary income
Ordinary income−¥855m2015-01-01 → 2015-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥726m2014-01-01 → 2014-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥625m2013-01-01 → 2013-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.1bn2017-01-01 → 2017-12-31StandaloneIncome before income taxes
Profit before tax−¥928m2016-01-01 → 2016-12-31StandaloneIncome before income taxes
Net income−¥1.1bn2017-01-01 → 2017-12-31StandaloneProfit loss
Net income−¥931m2016-01-01 → 2016-12-31StandaloneProfit loss
Net income−¥857m2015-01-01 → 2015-12-31dStandaloneNet income loss (5-year summary)
Net income−¥739m2014-01-01 → 2014-12-31dStandaloneNet income loss (5-year summary)
Net income−¥636m2013-01-01 → 2013-12-31dStandaloneNet income loss (5-year summary)
Total assets¥3.5bnat 2017-12-31StandaloneAssets
Total assets¥3.1bnat 2016-12-31StandaloneAssets
Total assets¥4.0bnat 2015-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.0bnat 2014-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.7bnat 2013-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥594mat 2017-12-31StandaloneLiabilities
Total liabilities¥523mat 2016-12-31StandaloneLiabilities
Net assets / equity¥2.9bnat 2017-12-31StandaloneNet assets
Net assets / equity¥2.6bnat 2016-12-31StandaloneNet assets
Net assets / equity¥3.5bnat 2015-12-31dStandaloneNet assets
Net assets / equity¥4.4bnat 2014-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥5.1bnat 2013-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.9bnat 2017-12-31StandaloneCash and deposits
Cash and deposits¥2.6bnat 2016-12-31StandaloneCash and deposits
Cash & equivalents¥1.9bnat 2017-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.4bnat 2016-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2015-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥1.2bnat 2014-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥5.4bnat 2013-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.1bn2017-01-01 → 2017-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥903m2016-01-01 → 2016-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥756m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥814m2014-01-01 → 2014-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥599m2013-01-01 → 2013-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥132m2017-01-01 → 2017-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥257m2016-01-01 → 2016-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥1.8bn2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.4bn2014-01-01 → 2014-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥110m2013-01-01 → 2013-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.5bn2017-01-01 → 2017-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥6m2016-01-01 → 2016-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥120m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥233,0002014-01-01 → 2014-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥5.4bn2013-01-01 → 2013-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-106.232017-01-01 → 2017-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-101.182016-01-01 → 2016-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-93.352015-01-01 → 2015-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-80.552014-01-01 → 2014-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-94.332013-01-01 → 2013-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥263.54at 2017-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥283.43at 2016-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥381.27at 2015-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥476.03at 2014-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥561.17at 2013-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio82.9%at 2017-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2016-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2015-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2014-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio89.3%at 2013-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued11,086,000at 2017-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,234,600at 2016-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,800at 2015-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,200at 2014-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,076,900at 2013-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees29at 2017-12-31StandaloneNumber of employees
Employees30at 2016-12-31StandaloneNumber of employees
Employees29at 2015-12-31dStandaloneNumber of employees
Employees28at 2014-12-31dStandaloneNumber of employees
Employees22at 2013-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 24
SegmentItemPeriodValue
Reconciling Itemsreconcilingdepreciation2017-01-01 → 2017-12-31¥1m
Reconciling Itemsreconcilingsegment profit2017-01-01 → 2017-12-31−¥537m
Diagnostic Divisionreportable segmentrevenue2017-01-01 → 2017-12-31¥33m
Diagnostic Divisionreportable segmentrevenue external2017-01-01 → 2017-12-31¥33m
Diagnostic Divisionreportable segmentsegment profit2017-01-01 → 2017-12-31−¥104m
Pharmaceutical Divisionreportable segmentrevenue2017-01-01 → 2017-12-31¥197m
Pharmaceutical Divisionreportable segmentrevenue external2017-01-01 → 2017-12-31¥197m
Pharmaceutical Divisionreportable segmentsegment profit2017-01-01 → 2017-12-31−¥438m
Total Of Reportable Segments And Otherssegment totalrevenue2017-01-01 → 2017-12-31¥229m
Total Of Reportable Segments And Otherssegment totalrevenue external2017-01-01 → 2017-12-31¥229m
Total Of Reportable Segments And Otherssegment totalsegment profit2017-01-01 → 2017-12-31−¥542m
Reconciling Itemsreconcilingdepreciation2016-01-01 → 2016-12-31¥4m
Reconciling Itemsreconcilingsegment profit2016-01-01 → 2016-12-31−¥438m
Diagnostic Divisionreportable segmentdepreciation2016-01-01 → 2016-12-31¥11m
Diagnostic Divisionreportable segmentrevenue2016-01-01 → 2016-12-31¥60m
Diagnostic Divisionreportable segmentrevenue external2016-01-01 → 2016-12-31¥60m
Diagnostic Divisionreportable segmentsegment profit2016-01-01 → 2016-12-31−¥105m
Pharmaceutical Divisionreportable segmentrevenue2016-01-01 → 2016-12-31¥119m
Pharmaceutical Divisionreportable segmentrevenue external2016-01-01 → 2016-12-31¥119m
Pharmaceutical Divisionreportable segmentsegment profit2016-01-01 → 2016-12-31−¥318m
Total Of Reportable Segments And Otherssegment totaldepreciation2016-01-01 → 2016-12-31¥11m
Total Of Reportable Segments And Otherssegment totalrevenue2016-01-01 → 2016-12-31¥178m
Total Of Reportable Segments And Otherssegment totalrevenue external2016-01-01 → 2016-12-31¥178m
Total Of Reportable Segments And Otherssegment totalsegment profit2016-01-01 → 2016-12-31−¥423m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 712
ItemContextValueUnit
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration_NonConsolidatedMember6423000JPY
Net cash provided by used in financing activities (5-year summary)CurrentYearDuration_NonConsolidatedMember1476503000JPY
Cash and cash equivalents (5-year summary)Prior4YearInstant_NonConsolidatedMember5404610000JPY
Cash and cash equivalents (5-year summary)Prior3YearInstant_NonConsolidatedMember1182466000JPY
Cash and cash equivalents (5-year summary)Prior2YearInstant_NonConsolidatedMember2060252000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant_NonConsolidatedMember1418993000JPY
Cash and cash equivalents (5-year summary)CurrentYearInstant_NonConsolidatedMember1922454000JPY
Number of employeesPrior4YearInstant_NonConsolidatedMember22
Number of employeesPrior3YearInstant_NonConsolidatedMember28
Number of employeesPrior2YearInstant_NonConsolidatedMember29
Number of employeesPrior1YearInstant_NonConsolidatedMember30
Number of employeesCurrentYearInstant_NonConsolidatedMember29
Average number of temporary workersPrior4YearInstant_NonConsolidatedMember4
Average number of temporary workersPrior3YearInstant_NonConsolidatedMember7
Average number of temporary workersPrior2YearInstant_NonConsolidatedMember7
Average number of temporary workersPrior1YearInstant_NonConsolidatedMember6
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember6
Number of shares heldCurrentYearInstant_No1MajorShareholdersMember727200
Shareholding ratioCurrentYearInstant_No1MajorShareholdersMember0.0655
Number of shares heldCurrentYearInstant_No2MajorShareholdersMember684600
Shareholding ratioCurrentYearInstant_No2MajorShareholdersMember0.0617
Number of shares heldCurrentYearInstant_No3MajorShareholdersMember320700
Shareholding ratioCurrentYearInstant_No3MajorShareholdersMember0.0289
Number of shares heldCurrentYearInstant_No4MajorShareholdersMember287800
Shareholding ratioCurrentYearInstant_No4MajorShareholdersMember0.0259
Number of shares heldCurrentYearInstant_No5MajorShareholdersMember183100
Shareholding ratioCurrentYearInstant_No5MajorShareholdersMember0.0165
Number of shares heldCurrentYearInstant_No6MajorShareholdersMember130000
Shareholding ratioCurrentYearInstant_No6MajorShareholdersMember0.0117
Number of shares heldCurrentYearInstant_No7MajorShareholdersMember124100
Shareholding ratioCurrentYearInstant_No7MajorShareholdersMember0.0111
Number of shares heldCurrentYearInstant_No8MajorShareholdersMember113798
Shareholding ratioCurrentYearInstant_No8MajorShareholdersMember0.0102
Number of shares heldCurrentYearInstant_No9MajorShareholdersMember101300
Shareholding ratioCurrentYearInstant_No9MajorShareholdersMember0.0091
Number of shares heldCurrentYearInstant_No10MajorShareholdersMember93600
Shareholding ratioCurrentYearInstant_No10MajorShareholdersMember0.0084
Number of shares heldCurrentYearInstant2766198
Shareholding ratioCurrentYearInstant0.2490
Cash and depositsPrior1YearInstant_NonConsolidatedMember2564045000JPY
Cash and depositsCurrentYearInstant_NonConsolidatedMember2867512000JPY
Accounts receivable tradePrior1YearInstant_NonConsolidatedMember66351000JPY
Accounts receivable tradeCurrentYearInstant_NonConsolidatedMember88736000JPY
Finished goodsPrior1YearInstant_NonConsolidatedMember13403000JPY
Finished goodsCurrentYearInstant_NonConsolidatedMember11807000JPY
Work in processPrior1YearInstant_NonConsolidatedMember－JPY
Work in processCurrentYearInstant_NonConsolidatedMember4931000JPY
SuppliesPrior1YearInstant_NonConsolidatedMember1715000JPY
SuppliesCurrentYearInstant_NonConsolidatedMember1842000JPY
Advance payments otherPrior1YearInstant_NonConsolidatedMember52556000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2016-12-31pass rounding
balance sheet identitynon_consolidated 2017-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2015-12-31pass
statement vs summary · net assetsnon_consolidated 2016-12-31pass
statement vs summary · net assetsnon_consolidated 2017-12-31pass
statement vs summary · operating cash flownon_consolidated 2016-01-01/2016-12-31pass
statement vs summary · operating cash flownon_consolidated 2017-01-01/2017-12-31pass
statement vs summary · revenuenon_consolidated 2016-01-01/2016-12-31pass
statement vs summary · revenuenon_consolidated 2017-01-01/2017-12-31pass
statement vs summary · total assetsnon_consolidated 2016-12-31pass
statement vs summary · total assetsnon_consolidated 2017-12-31pass